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Background: Atherosclerotic renal artery stenosis (RAS) is the most common cause of secondary hypertension. Renal
stenting has become the treatment of choice for RAS in most centers. Primary patency of RAS is well defined, but limited
data are available on outcomes of secondary interventions for treatment of in-stent restenosis.
Methods: This was a retrospective analysis of a 10-year experience with renal artery stenting in patients presenting with
recurrent symptomatic stenosis. End points included freedom from tertiary procedures, change in baseline renal function
by >20% measured by estimated glomerular filtration rate (eGFR), patency confirmed by duplex imaging, long-term
hypertension response, freedom from hemodialysis, and survival.
Results:We reviewed 948 patients with 1150 treated renal arteries. Of these, 107 patients (122 renal stents) returned with
symptomatic in-stent restenosis and required reintervention (target vessel revascularization [TVR] rate, 10.6%): 97% had
recurrent or worsening hypertension, and 67% had worsening renal function. There were 69 women (64%) and 38 men
(35%) with an average age of 68.9 years. Mean follow-up was 35.5 months (range, 1.0-104.7 months) for patency and
37.7 months (range, 0.03-100.9 months) for renal function (creatinine). Secondary interventions included 27 percuta-
neous transluminal angioplasties (PTAs), 10 PTAs with cutting balloon, 77 repeat renal artery stenting, and 8 placements
of drug-eluting stents (DES). Twenty-five of the 122 arteries (20%) required tertiary interventions in 23 patients, a
significantly higher TVR rate vs de novo interventions (11%; P  .003). Freedom from tertiary interventions at 60
months was similar among treatment groups undergoing PTA (66%), cutting balloon (100%), stent (80%), and DES
(75%; P  .348). Seventeen (16%) had an increase of >20%, 50 (47%) had a decrease of >20%, and 30 (28%) had no change
in renal function. Ultimately 25 (23%) remained or progressed to renal failure (eGFR < 30%), and 8 required hemodialysis.
The survival rate was 73% at 5 years. Mean follow-up for long-term hypertension response was 3.2 years, with 56% improved,
28% with no improvement or deterioration, 16% without long-term data available, and no patients cured.
Conclusions: Secondary interventions for renal in-stent restenosis had higher TVR vs de novo renal stents in this large
series (21% vs 11%; P  .003). Definitive recommendations on the best secondary treatment strategy cannot be made
because a medical treatment control group was not available for comparison. (J Vasc Surg 2011;53:1026-31.)
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aRenal artery bypass surgery has long been the standard
of care for the management of atherosclerotic renal artery
stenosis for both hypertension and renal insufficiency.
However, significant morbidity and mortality have been
reported after surgical reconstruction.1,2 During the past
decade, an increasing enthusiasm for minimally invasive
techniques has changed the first line of therapy to
percutaneous-based procedures in most institutions. Renal
angioplasty with adjunct stent placement has been widely
reported since the introduction of the endovascular era,
with good technical results andminimal perioperative com-
plications.3-5 Currently, there is great controversy regard-
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1026ng the utility of renal artery stenting compared with med-
cal therapy. However, renal artery stenting has continued
o be widely performed for the treatment of symptomatic
enal artery stenosis.
We previously reported our extensive experience with
enal stenting for atherosclerotic lesions.6-8 Factors affect-
ng the need for target vessel revascularization (TVR) after
enal stenting include solitary kidney, stent diameter 5
m, age67 years, peripheral arterial disease, and stroke.6
ew studies have analyzed the management of recurrent
ymptomatic renal in-stent stenosis.9,10 This study evalu-
ted the outcome of percutaneous endoluminal therapy in
atients with symptomatic in-stent restenosis.
ETHODS
Study design. This was a retrospective, nonrandom-
zed, single-cohort analysis conducted at Charleston Area
edical Center West Virginia University and approved by
ur governing Institutional Review Board. This study was
onducted in accordance with the Health Insurance Porta-
ility and Accountability Act requirements and the prevail-
ng ethical principles governing research.11
Participants. This study was a 10-year retrospective
eview (1999-2009) of renal artery stenting. The hospital
dministrative billing database was used to identify poten-
ial study participants using the International Classification
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Volume 53, Number 4 Stone et al 1027of Disease Codes, 9th edition. The study cohort was created
by reviewing electronic medical records of the potential
participants with recurrent symptomatic stenosis to identify
all patients where the index renal artery procedure included
the placement of a renal artery stent and then later required
a second intervention. Thus, all patients who did not have
at least one follow-up intervention for the same target stent
placement were excluded from further analysis. Baseline
characteristics, comorbid conditions at the time of the
index procedure, and procedural and artery-specific infor-
mation were collected during the electronic medical re-
cords review.
The primary objective of this study was to determine
long-term outcomes for the treatment of symptomatic
in-stent stenosis and compare secondary intervention treat-
ment modalities. Secondary objectives included analysis of
risk of renal occlusion, in-stent restenosis, and risk of he-
modialysis during follow-up.
Study definitions. The treatment or secondary inter-
vention was not randomized or assigned by the researchers
but was chosen by the vascular interventionist. The institu-
tional standard was to dilate the lesion with a standard
balloon or cutting balloon (CB) and place a stent for
persistent gradient, residual stenosis on angiography or
intravascular ultrasound imaging, and/or residual disease
outside the previously stented segment. Covered stents
have been reserved for tertiary intervention and drug-
eluting stents (DES) have been used for small vessels with
diffuse in-stent restenosis. The eGFR was defined as 186.3
serum creatinine1.154  age0.203  0.742 (if female) 
1.212 (if African American). Change in renal function was
defined as increased if the eGFR increased by 20%, as
decreased if the eGFR decreased by 20%, and as stayed
the same if the change in eGFR was20%. Response in the
hypertensive patients were defined by the following:
● “Cured” patients were normotensive with systolic
blood pressure140 mmHg and diastolic pressure
90 mm Hg without medications.
● “Improved” patients were normotensive defined as
above, on the same number of medications (improved
or reduced number of medications).
● “No effect” patients had no change or inability tomeet
the above criteria.
The medication regimen was reviewed at the time of
secondary intervention and compared with last clinical
follow-up with hospital medication reconciliation records.
Comparison groups were selected by grouping patients
who were treated with the same type of secondary interven-
tion. For the current study, there were four types of sec-
ondary intervention: (1) percutaneous angioplasty (PTA)
only, (2) PTA with the use of a CB, (3) PTA with place-
ment of bare-metal stent (re-stenting), and finally, (4) PTA
with placement of a DES.
Treatment protocol. Patients were routinely evalu-
ated at 1, 6, and 12 months and then annually in our
vascular center. Patients with worsening hypertension were
defined by systolic blood pressure  140 mm Hg or wiastolic blood pressure90 mmHg. In-stent stenosis was
efined by a peak systolic velocity (PSV) 180 cm/s and
enal aortic ratio 3.5. Patients were not offered repeat
ngiography with duplex criteria alone.
Outcomes. The primary end point was the need for a
hird intervention, which was defined as a repeat procedure,
eferred to as TVR. Other end points included a change in
aseline renal function of 20%; patency confirmed by
uplex imaging; in-stent restenosis defined as any or all of
he following occurrences: a tertiary intervention, failed
atency (confirmed by duplex imaging or angiography) or
SV 180 and renal/aortic ratio of 3.5; freedom from
emodialysis, hypertension response to treatment at the
ast clinical follow-up, and patient survival. The timing of
n-stent restenosis was determined by the date of the first
ccurrence (1) tertiary intervention, (2) failed patency, or
3) when the duplex threshold was exceeded. Death was
etermined from hospital records or the Social Security
eath Index.
Statistical analysis. All analyses were performed using
PSS 17.0 software (SPSS Inc, Chicago Ill). Descriptive
tatistics are expressed in terms of frequencies, percentages,
r means and standard deviation (SD). Categoric variables
ere tested by 2 or Fisher exact tests, and continuous
ariables were tested by the t test or analysis of variance,
here deemed appropriate. A value of P .05 was consid-
red significant. Survival and freedom from event curves
ere created by using the Kaplan-Meier method, compared
y the log rank test, and graphically presented using life
ables.
The study period did not have a single final end date for
ll outcome measures. The freedom from event for each
utcome was calculated independently and was based on
he absolute date of the last measurement for each outcome
easurement. In other words, for each study end point,
lapsed study time was calculated based on treatment date
o the time of the last recorded measurement.
ESULTS
We reviewed 948 patient records comprising 1150
reated renal arteries. The final analysis included 107 pa-
ients with 122 lesions who met the inclusion criteria. The
VR rate for primary intervention was 11.0% (122 of
150). The overall mean age for the study cohort was 68.9
ears (SD, 9.7), and there were 69 women (65.0%) and 38
en (36.0%). The main indications for reintervention were
ecurrent or worsening hypertension (97%) and worsening
enal function (69%).
The mean time to secondary intervention was 19.6
onths (SD, 16.6; range, 0.4-73.7 months). Thus, 50%
equired reintervention2 years (Fig 1). Secondary proce-
ural success, defined as residual stenosis 30%, was
chieved in 121 of 122 (99%). Of the secondary proce-
ures, 77 (63%) involved the placement of bare stents, 27
nderwent PTA (22%), 10 (8%) were associated with CB,
nd 8 (7%) were DES. No significant baseline differences
ere found among the four treatment groups (Table I).
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TVR. After secondary interventions, 25 of the 122
arteries (21.0%) required tertiary interventions in 23 pa-
tients. TVR rates for secondary interventions for in-stent
stenosis were significantly higher than the rates for the
initial renal artery stenting procedures (21% vs 11%; P 
.003). TVR rates among the treatment groups were 30.0%
(8 of 27) for PTA, 0% (0) for CB, 20% (15 of 77) for stent,
and 25% (2 of 8) for DES (P .250). The mean follow-up
for the primary end point (repeat tertiary procedure) was
46.1 months (SD, 28.2; range, 1.2-124.1 months). The
rates of freedom from tertiary interventions at 60 months
were similar among treatment groups at 66% for PTA,
100% for CB, 80% for stent, and 75% for DES (P .348 by
log rank; Fig 2).
Stent occlusion. The mean follow-up for renal stent
occlusion (measured by duplex ultrasound imaging) was
35.5 months (range, 0.9-104.7). Follow-up duplex ultra-
sound imaging was available for 108 of 122 arteries (89%),
and 5 (5%) were occluded. The rates of freedom from
Fig 1. Freedom from secondary interven
Table I. Baseline characteristics of the 107 patients
Arteries PTA
Variable
Patients, N  107
(n  122)a (n  27)a
No. (%) No. (%)
Hypertension 119 (97.5) 27 (100.0)
Diabetes 39 (32.0) 12 (44.4)
Hyperlipidemia 85 (69.7) 22 (81.5)
Renal failure 32 (26.2) 7 (25.9)
Tobacco use 44 (36.1) 11 (40.7)
CHF 20 (16.4) 5 (18.5)
CAD 69 (56.6) 18 (66.7)
COPD 24 (19.7) 6 (22.2)
PVD 67 (54.9) 11 (40.7)
Single kidney 14 (11.5) 0 (0.0)
Mean (SD) Mean (SD)
Stent diameter, mm 5.2 (0.7) 5.4 (0.7)
Stent length, mm 14 (2.5) 13.9 (2)
CAD,Coronary artery disease;CB, cutting balloon;CHF, congestive heart fa
peripheral vascular disease; SD, standard deviation.
aData reflect the number of arteries.occlusion were significantly different among treatment iroups: 95% for PTA, 100% for CB, 96% for stent, and 0%
or DES (P  .0001 by log rank).
In-stent restenosis. The mean follow-up for the in-
tent restenosis end point in this cohort, as measured by
VR, stent occlusion, or duplex ultrasound imaging, was
9.7 months (range, 0.9-104.7 months). Freedom from
n-stent restenosis was similar among treatment modalities
t 60 months for PTA, CB (50-month max), stent, and
ES (58-month max) groups: 32%, 40%, 46%, and 58%,
espectively (P  .798 by log rank; Fig 3).
Renal function. The mean time to secondary interven-
ion was 19.6 months, and baseline and secondary creatinine
alues were both obtained for 104 participants (97%) before
he interventions. The percentage change in renal function
as calculated by considering the difference in eGFR from
aseline to the time of the secondary intervention. Of the 107
atients, 72 (67%) had an increase of20% in renal function,
9 (18%) had a decrease in renal function of20%, 13 (12%)
tayed the same, and 3 (3%) did not have a secondary creati-
ine value. Thus, the renal function for 85 patients (79%)
The error bars show the standard error.
CB Stent DES
P
(n  10)a (n  77)a (n  8)a
No. (%) No. (%) No. (%)
0 (100.0) 74 (96.1) 8 (100.0) .615
4 (40.0) 20 (26.0) 3 (37.5) .306
6 (60.0) 51 (66.2) 6 (75.0) .430
1 (10.0) 23 (29.9) 1 (12.5) .445
3 (30.0) 24 (31.2) 6 (75.0) .091
2 (20.0) 12 (15.6) 1 (12.5) .958
7 (70.0) 39 (50.6) 5 (62.5) .381
1 (10.0) 14 (18.2) 3 (37.5) .490
5 (50.0) 48 (62.3) 3 (37.5) .173
1 (10.0) 12 (15.6) 1 (12.5) .186
ean (SD) Mean (SD) Mean (SD)
5.1 (0.7) 5.2 (0.8) 5.1 (0.7) .605
5.6 (2.4) 13.8 (2.7) 14 (2.7) .203
ES, drug-eluting stent; PTA, percutaneous transluminal angioplasty; PVD,1
M
1
ilure;Dmproved or remained stable.
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ond intervention was 37.7 months (range, 0.03-100.9
months): 17 (16%) had an increase of20%, 50 (47%) had
a decrease in renal function of 20%, 30 (28%) stayed the
same, and 10 (9%) did not have follow-up creatinine levels
(Fig 4). As calculated from the last eGFR, 25 patients (23%)
ultimately remained or progressed to renal failure (eGFR
30 mL/min), and 8 patients required hemodialysis. In-
terventions were performed on four of the eight (50%)
contralateral renal arteries for the dialysis participants (Ta-
ble II).
Long-term hypertension. The mean follow-up for
the long-term hypertension end point was 3.2 years (SD,
2.0; range, 0.1-8.3 years). At the time of the secondary
intervention, 90 of the 107 participants (84%) had a med-
ication screen, and another follow-up screen was performed
at the last available clinic medication reconciliation. No
patients were cured of hypertension, and no antihyperten-
sive medication follow-up data were available for 17 pa-
tients (16%). Blood pressure control was improved in 28
patients (26%) while taking the same number of antihyper-
Fig 2. Freedom from tertiary intervention by treatment
balloon; DES, drug-eluting stent; PTA, percutaneous tra
Fig 3. Freedom from in-stent restenosis by treatment group. The
error bars show the standard error. CB, Cutting balloon; DES,
drug-eluting stent; PTA, percutaneous transluminal angioplasty.tensive medications, and 32 patients (30%) had improve- aent in blood pressure control and reduced the number of
ntihypertensive medications. No change in blood pressure
ontrol was found for 10 patients (9%), and blood pressure
ontrol deteriorated in 20 patients (19%; see bottom of Fig
). Overall, patient survival was 73% at 5 years.
ISCUSSION
To our knowledge, this is the largest current series that
as been reported on the management of patients with
ymptomatic in-stent restenosis. This series demonstrates
p. The error bars show the standard error. CB, Cutting
inal angioplasty.
ig 4. Long-term renal function changes and long-term hyper-
ensive response.grougain, compared with primary intervention, that repeat
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stenosis, with no perioperative mortality of the 107 treated
patients. Therefore, we feel confident that percutaneous-
based intervention for recurrent symptomatic disease pro-
vides a safe method for management.
Despite the apparent safety, there are issues that affect
long-term durability after repeat intervention. As known,
the technique used to manage the in-stent stenosis can
affect the subsequent patency of the intervention. Angio-
plasty alone with a semicompliant balloon was used in
nearly 25% of our patients, with 30% requiring tertiary
interventions. In 10% of patients, we used CB angioplasty,
and none of these patients ultimately required a repeat
intervention. Our results were comparable to those of
Zeller et al,12 with the exception of the results demon-
strated with CBs. They demonstrated that the use of a CB
was an independent risk factor for worsened patency com-
pared with other techniques.12
Most patients in our series were treated with repeat
placement of a bare-metal balloon-expandable stent, and
21% subsequently required a third procedure, a signifi-
cantly higher percentage compared with 11% requiring a
second procedure. Themost likely reason for this difference
is that the cohort of patients who require a second inter-
vention for in-stent restenosis have already demonstrated a
propensity for restenosis, and it is not surprising that they
have higher rates of tertiary procedures when using the
same modality of treatment as the original procedure.
Interestingly, there was a difference in the time that it
Table II. Patients subsequently requiring hemodialysis
Never treated/
treated 60%
Creatinine
at TVR Time from TVR to HD
Treated
60%/Occ
Normal 1.7 4 years required AAA stent and 3rd
procedure peristent procedure
HD 2 months of EVAR
Occluded 1.5 4 years 11 months later and 2
additional stents
Stented 60% 3 4 years 3 months later
Normal 1.7 4 years 8 months later: duplex 2
years after severe stenosis: PSV
429/5.2/12.2 cm/0.77
Bilateral repeat 2 8 months later HD started creatine
stable at d/c at time of HD
normal duplex bilateral
Normal 3.1 21 months later HD, kidney size
8.6 cm from 9.9
Bilateral repeat 5.8 31 months later creatinine 2.0, HD
4 years 8 months after TVR,
duplex patent and normal
velocities at time of HD
Stented 60% 1.7 34 months later HD after
peripheral angiogram and duplex
renal; both renals patent
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair;
HD, hemodialysis; Occ, occlusion; PSV, peak systolic velocity; TVR, target
vessel revascularization.took for TVR to occur. The mean time to intervention in rhis cohort was 46.1 months, which was longer compared
ith 19.6 months in the original stent placement group.
his increased time to intervention and, considering that
he length of follow-up was 12 years for this study com-
ared with 10 years in the original study, may have allowed
ore time for TVR to occur in this study.
Balloon angioplasty alone was the second most fre-
uently used technique for managing in-stent stenosis, and
ong-term outcomes were not statistically different from
hose of repeat stenting. This should not be extrapolated,
ecause angioplasty did just as well as stenting. Most pa-
ients appeared to have provisional stent placement for
ignificant recoil after angioplasty alone. However, in pa-
ients for whom the results of angioplasty were satisfactory
ith angiography, the durability appears similar.
We used a DES in eight patients, and two required a
hird intervention. Late occlusion eventually developed in
hree patients despite antiplatelet therapy. DESs have been
sed in the coronary arteries to provide a treatment modal-
ty with less in-stent restenosis than bare-metal stents.
owever, there are limited data regarding the treatment of
n-stent renal stenosis. Unfortunately, renal artery occlu-
ion subsequently developed in three of the eight patients
ho were treated in our series, which may be secondary to
atient selection in this group.
What we can see, based on looking at these select cases,
s that these stents were typically placed in small renal
rteries, because the platform for use is currently only for
reatment of smaller vessels (coronary arteries). In addition,
he first three arteries to receive DES occluded, which were
he ones with the longest follow-up. The other five arter-
es that received DES were time-censored out. However, it
annot be assumed that the other five DES patients would
ave progressed to occlusion, and longer follow-up is
eeded to determine true patency for DES. So therefore,
he worse outcome in this select group is probably signifi-
antly biased.
Our group has not routinely performed angiography
or ultrasound findings suggesting in-stent restenosis in
atients without symptoms. In addition, we have used
ative renal artery criteria for determination of renal artery
tenosis. Of our cohort, 20% of patients required tertiary
rocedures, 4% had stent occlusion, and an additional 22%
ad asymptomatic restenosis based on native renal artery
tenosis criteria (PSV, 180 cm/s; renal aortic ratio 3.5).
o consensus has been reached on the appropriate criteria
fter renal stenting, however Chi et al have suggested that
he PSV criteria be raised to 395 cm/s and the renal
ortic ratio to 5.1.13
Another concern of repeat procedures on the renal
rtery is the long-term effect on renal function. We are
naware of any reported data that provide the natural
istory of untreated severe in-stent renal artery stenosis.
ur current data are similar to the results of our previously
eported cohort for initial stenting procedures, as well as
he results previously reported by Davies et al,10 where 22%
f the restenosis patients had increases in creatinine and 9%
equired hemodialysis. In our group, 8 of 107 patients
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plained by selection bias because our center recommends
TVR only in the presence of an abnormal duplex study,
with clinical recurrence as defined by worsening creatinine
or hypertension. Thus, patients with tenuous renal status
were more likely to undergo intervention.
However, one could also speculate procedurally related
occult embolization was to blame, and renal artery bypass
may have been a better alternative. This is debatable, espe-
cially given the perioperative mortality of 10% for renal
artery bypass and the increasing small numbers of renal
artery bypasses being performed secondary to the increase
in renal artery stenting across the nation.14
Consideration could also be given to using embolic
protection devices for secondary intervention because there
are emerging data that its adjunctive use can decrease the
percentage of patients who have worsening renal function
after renal artery stenting. The small number of patients
needing TVR makes future randomized trials very diffi-
cult, and this most likely will continue to be a conun-
drum for vascular specialists with no panacea for these
difficult patients.
Of the eight patients requiring dialysis, six were women
(75%) and most required hemodialysis over 3 years after
their secondary procedure. Table II demonstrates the status
of the contralateral artery for the eight dialysis patients;
only one involved a solitary kidney, whereas two patients
underwent repeated bilateral interventions. Survival after
repeat interventions appears to be similar to that of primary
interventions. This series provides long-term survival
follow-up, and 72% were still alive at 5 years.
Limitations of this study are typical of a retrospective
review. Hypertension response was determined by review-
ing hospital records at the last clinical evaluation. The
number of antihypertensive medications was also collected
and compared with the number of medications at the time
of the secondary intervention.
Another limitation is selection bias for repeat angiog-
raphy in patients with severe baseline chronic kidney disease
vs patients with normal renal function. This may have
selected a cohort of patients with worsening renal function
that could be secondary to other causes (ie, diabetic ne-
phropathy) vs ischemic nephropathy.
And finally, the current study perhaps lacked the power
to draw any strong conclusions. For example, a sample size
of 54 (27 in each group) would be required to test and
detect a significant difference in TVR rates between CB
(0%, 0 of 10) and DES (25%, 2 of 8) based on 80% power
and a two-tailed test. Despite these limitations, however,
the current study is one of the largest of its type and
provides a contrast to other published literature.
CONCLUSIONS
Secondary interventions for renal in-stent restenosis
had higher TVR compared with de novo renal stents in this
large series (21% vs 11%; P  .003). Definitive recommen- Sations on the best secondary treatment strategy cannot be
ade in this retrospective study and no control group
ithout secondary procedures.
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